Nantes, France – June 24, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has entered into a commercial and revenue sharing agreement with a leading global center in research and treatment against cancer, based in New York.
This global and exclusive agreement with Memorial Sloan Kettering Cancer Center (MSK) covers rights attached to patents of OSE Immunotherapeutics and patents co-owned with MSK in the area of CAR (Chimeric Antigen Receptor) cell therapies in the treatment of cancers expressing the Interleukin-7 Receptor (IL-7R), in particular hematological tumors such as Acute Lymphoblastic Leukemia. Under the agreement, MSK will conduct research, development and commercialization activities and subsequently share potential revenues with OSE Immunotherapeutics.